Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Kit

Products from BPS Bioscience require a minimum order value above 400€

Application: Study CD19:CD3 complex formation and assess the binding of BsAbs to their dual-antigen targets simultaneously for drug discovery and high throughput screening (HTS). Note: Suitable for use with human serum, cell culture supernatants, and with purified proteins.

Background: Bispecific antibodies (BsAbs) are antibodies that have binding sites directed against different antigens or different epitopes of the same antigen. They are composed of heavy and light chains, and the appropriate chain matching is required for efficacy. To enhance the chance of chain matching and different applications, more than 30 different technologies have been developed, such as knob-into hole, ART-Ig, BiTE (bispecific cell engager) and others. They have gained attention for the treatment of cancer and other disorders due to their superior cytotoxicity effects and less development of resistance to their use. BsAbs can act as immune cell-cancer cell bridges, enhancing the killing potential of the immune cells. Current BsAbs have a CD3, CD16 or CD47 as one of the binding domains, and target CD19, PD-1, LAG-3, PSMA, mesothelin or other tumor antigens with the other. B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3C, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells, and is involved in the balance of humoral, antigen-induced and tolerance responses. Its presence in normal and neoplasmic B cells has made it an attractive target in cancer therapy. Blinatumomab is a CD19/CD3 BiTE already approved by the FDA for use in patients with refractory or relapsed B-cell precursor ALL (acute lymphoblastic leukemia), and now being considered in CLL (chronic lymphocytic leukemia) treatment. The development of new BsAbs targeting CD19 and CD3 and formats will continue to bring benefits to patients suffering from CD19⁺ cancer types.

Contraindications: This kit is compatible with up to 1% DMSO.

Description: The Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Kit is an ELISA designed to analyze the ability of Bispecific Antibodies (BsAbs) to bridge CD19 (cluster of differentiation 19) and CD3 (cluster of differentiation 3) for screening and profiling applications. This assay kit can determine if an anti-CD19-anti-CD3 bispecific antibody binds to both targets simultaneously and bridges CD19 to CD3. The Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Assay Kit comes with enough recombinant human CD19 (amino acids 20-291), CD3- Containing Detection Reagent, and assay buffer for 100 enzyme reactions. This kit also includes Anti-CD19-Anti-CD3 Bispecific Antibody as a positive control.Figure 1: Bispecific CD19:CD3 Bridging Chemiluminescence ELISA Assay Kit principle.A 96-well plate is coated with CD19 protein. After coating, an anti-CD19-anti-CD3 bispecific antibody is added in an optimized assay buffer. The plate is washed to remove unbound anti-CD19-anti-CD3 bispecific antibody. The plate is then incubated with CD3- Containing Detection Reagent. Finally, ELISA ECL substrate is added to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the bridging efficacy.

Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.

Warnings: Avoid freeze/thaw cycles

Biosafety Level: Not applicable (BSL-1)

References: Robinson H., et al., 2018 Blood 132 (5): 521-532.Ma J., et al., 2021 Front Immunol. 12:626616. 

• Artikelnummer: BPS82764
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 82764
• Verpackungseinheit: 96 reactions
• Mengeneinheit: PAK